ArticleDrug design, development and therapy2025
Elucidating the Differential Mechanisms of Jingui Shenqi Pill and Mingmu Dihuang Pill in the Treatment of Diabetic Nephropathy Based on Yin-Yang Theory.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A randomized controlled trial protocol of herbal formulas for modifying susceptible body constitution to enhance COVID-19 resistance in Hong Kong residents.Journal of thoracic disease · 2026Article
- TangShenWeiNing formula alleviates diabetic kidney disease by inhibiting ferroptosis via AMPK pathway in renal tubular epithelial cells.Frontiers in endocrinology · 2026Article
- Mechanisms of Microctis Folium in Hyperlipidemia: Integrating Serum Pharmacochemistry, Network Pharmacology, and Transcriptomics.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Yin-Yang attributes of MMDH and JGSQ in treating diabetic nephropathy (DN) remain unexplored. Methods: UPLC-MS identified formula components, network pharmacology analyzed common DN targets, and in vitro renal fibrosis models assessed efficacy. Transcriptomics revealed key pathways, and molecular docking simulated component-target interactions. Results: UPLC-MS confirmed the compositional complexity of MMDH and JGSQ. Network pharmacology indicated their involvement in multiple DN-related pathways. In vitro, JGSQ alleviated fibrosis and enhanced adhesion via FN and E-cad, while MMDH reduced interstitial fibrosis via FN and VIM. Transcriptomics showed JGSQ regulates the TGF-β pathway, and MMDH modulates the TNF pathway. Molecular docking confirmed key components binding to TGFB1 and TNFA. Conclusion: MMDH and JGSQ exhibit distinct chemical compositions, targets, and pathways, underscoring their Yin-Yang regulatory roles in kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.